Remogliflozin etabonate

For research use only.

Catalog No.S0993 Synonyms: GSK189075

CAS No. 442201-24-3

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity inhibitor of sodium glucose cotransporter (SGLT2) with Ki of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

Size Price Stock Quantity  
USD 677 In stock
USD 2039 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Biological Activity

Description Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity inhibitor of sodium glucose cotransporter (SGLT2) with Ki of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

Protocol

References

Solubility (25°C)

Chemical Information

Molecular Weight
Formula
CAS No. 442201-24-3
Storage powder
in solvent
Synonyms GSK189075
Smiles CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00575159 Completed Drug: GSK189075|Drug: placebo Diabetes Mellitus Type 1 GlaxoSmithKline March 31 2008 Phase 2
NCT00625859 Completed Drug: GSK189075|Drug: Bupropion|Drug: Placebo Diabetes Mellitus Type 2 GlaxoSmithKline January 16 2008 Phase 1
NCT00532610 Completed Drug: GSK189075 Type 2 Diabetes Mellitus|Diabetes Mellitus Type 2 GlaxoSmithKline September 2007 Phase 1
NCT00501930 Completed Drug: GSK189075 Type 2 Diabetes Mellitus|Diabetes Mellitus Type 2 GlaxoSmithKline April 2007 Phase 1
NCT00501397 Completed Drug: ketoconazole|Drug: GSK189075 Type 2 Diabetes Mellitus|Diabetes Mellitus Type 2 GlaxoSmithKline February 2007 Phase 1
NCT00376038 Completed Drug: GSK189075 oral tablets|Drug: metformin tablets Type 2 Diabetes Mellitus|Diabetes Mellitus Type 2 GlaxoSmithKline August 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Others Products

Tags: buy Remogliflozin etabonate | Remogliflozin etabonate supplier | purchase Remogliflozin etabonate | Remogliflozin etabonate cost | Remogliflozin etabonate manufacturer | order Remogliflozin etabonate | Remogliflozin etabonate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID